Frits van Rhee

High Impact

Professor

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

81 h-index 844 pubs 25,690 cited

Research Areas

Links

ORCID Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dr. Frits van Rhee's research centers on understanding and developing new treatments for hematological malignancies, with a particular focus on multiple myeloma and Castleman's Disease. He investigates the molecular underpinnings of these conditions, including the evolutionary pathways from smoldering myeloma to multiple myeloma and the role of the immune microenvironment in disease progression. His work also examines disparities in access to novel therapies, such as CAR-T cells and bispecific antibodies, for patients with multiple myeloma.

Dr. van Rhee is recognized as a world-leading expert in Castleman's Disease, having contributed to the validation of international clinical definitions for its subtypes. His research also addresses the risk of infections associated with advanced treatments like bispecific antibodies in multiple myeloma and evaluates the efficacy of these therapies in real-world settings.

With an extensive publication record, Dr. van Rhee has authored hundreds of manuscripts and abstracts and holds significant scholarship metrics, including an h-index of 81 and over 25,000 citations. He holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research at the University of Arkansas for Medical Sciences and collaborates extensively with colleagues within the institution.

Research Overview

Dr. Frits van Rhee received his medical degree at Erasmus University, Rotterdam, Netherlands, and his PhD at the Imperial College of Science, Medicine and Technology, University of London. He trained in internal medicine and hematology in the UK, and in bone marrow transplantation (BMT) at Oxford and the Royal Postgraduate Medical School in London. Dr. van Rhee is a professor of medicine and director of developmental and translational medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. He also holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research. Dr. van Rhee holds memberships in the International Society for Experimental Hematology, the International Society for Cellular Therapy, and the European Group for Bone and Marrow Transplantation. He serves on the editorial review boards for Annals of Hematology, Bone Marrow Transplantation, and Cytotherapy. He has written hundreds of manuscripts and abstracts, as well as presented at scientific meetings. Dr. van Rhee's current research focuses on immunotherapy for myeloma. Dr. van Rhee is also a world-leading expert in Castleman's Disease.PublicationsMake an appointment with the UAMS Myeloma Institute

Metrics

h-index: 81
Publications: 844
Citations: 25,690

Selected Publications

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025) DOI
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry (2025) DOI
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024) DOI
Deciphering the genetics and mechanisms of predisposition to multiple myeloma (2024) DOI
Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease (2024) DOI
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (2024) DOI
Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma (2024) DOI
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI
Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease (2024) DOI
Modulation of Hematopoietic Injury by a Promising Radioprotector, Gamma-Tocotrienol, in Rhesus Macaques Exposed to Partial-Body Radiation (2023) DOI
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances (2023) DOI
Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study (2023) DOI
Perspectives on the Treatment of Multiple Myeloma (2023) DOI
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023) DOI
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes (2023) DOI

Grants & Funding

Qualitative Research in Castleman's Disease: Exploring Patients' Perspectives through Interviews, Project #A2-7438 United BioSource Corporation Principal Investigator
UARK 2006-41 A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal lgG1 antibody) in Subjects with Adva Protein Design Labs, Inc Principal Investigator
UARK 2004-61: (AMD3100-3102) A Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 ug/kg) plus G-CSF (10 ug/k AnorMED, Inc. Principal Investigator
No FP attached Janssen Research & Development, LLC Principal Investigator
2004-23: (Protocol C0328T03) A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Administered Biweekly as an Intravenous Infusion Centocor, Inc. Principal Investigator
KAG 301-Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (Kos 953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Genzyme Principal Investigator
No FP attached AbbVie Inc Principal Investigator
UARK# 2012-02 TOTAL THERAPY 5B: A PHASE II TRIAL FOR HIGH-RISK MYELOMA EVALUATING Onyx Pharmaceuticals, Inc. Principal Investigator